EIKN

+ Watchlist + Portfolio

Eikon Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $12.01
52-Week Range: $7.90 – $17.40
Market Cap: $582.27M
P/E (TTM): —
EPS (TTM): -5.95
Dividend Yield: —

Advanced Metrics

Price/Book: 1.25
PEG Ratio: —
Return on Equity: —
Return on Assets: —
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 9.89
Debt/Equity: 0.54
Total Debt: $252.22M
Free Cash Flow: —
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $371.56M

EIKN Income statement, annual periods, in USD
USD	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00
Research & Development	$207.26M	$204.54M	$250.32M
Selling, General & Admin	$58.48M	$55.81M	$88.63M
Operating Expenses	$265.74M	$260.34M	$338.94M
Operating Income	-$265.74M	-$260.34M	-$338.94M
EBITDA	-$224.21M	-$218.39M	-$299.24M
Pretax Income	-$242.00M	-$243.81M	-$324.25M
Net Income	-$242.00M	-$243.81M	-$324.25M
Diluted EPS	-7.40	-7.45	-6.18
Diluted Shares	32.71M	32.71M	53.98M

EIKN Balance Sheet statement, annual periods, in USD
USD	FY2023	FY2024	FY2025
Cash & Equivalents	$112.78M	$129.18M	$104.90M
Current Assets	$436.43M	$227.89M	$348.92M
Total Assets	$525.71M	$491.24M	$594.73M
Current Liabilities	$31.44M	$56.45M	$55.01M
Total Debt	$31.73M	$202.46M	$257.32M
Total Liabilities	$867.08M	$1.06B	$1.47B
Retained Earnings	-$361.13M	-$604.94M	-$920.51M
Shareholders' Equity	-$341.37M	-$571.93M	-$879.03M
Working Capital	$404.99M	$171.44M	$293.91M

EIKN Cash Flow statement, annual periods, in USD
USD	FY2023	FY2024	FY2025
Operating Cash Flow	-$190.85M	-$134.80M	-$188.52M
Capital Expenditure	-$28.51M	-$84.80M	-$46.74M
Free Cash Flow	-$219.36M	-$219.60M	-$235.26M
Depreciation & Amortisation	$17.75M	$25.39M	$24.18M
Stock-Based Compensation	$9.54M	$12.43M	$18.04M
Investing Cash Flow	$136.95M	$151.35M	-$181.34M
Financing Cash Flow	$105.81M	$244.00K	$352.05M
Net Change in Cash	$51.91M	$16.80M	-$17.81M

EIKN Income statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$53.86M	$56.59M	$65.23M	$70.05M
Selling, General & Admin	$13.92M	$14.80M	$17.94M	$17.29M
Operating Expenses	$67.78M	$71.38M	$83.17M	$87.34M
Operating Income	-$67.78M	-$71.38M	-$83.17M	-$87.34M
EBITDA	-$58.70M	-$64.92M	-$74.60M	-$82.22M
Pretax Income	-$64.92M	-$68.24M	-$79.66M	-$82.96M
Net Income	-$64.92M	-$68.24M	-$79.66M	-$82.96M
Diluted EPS	—	-2.28	—	-2.46
Diluted Shares	—	32.71M	—	33.70M

EIKN Balance Sheet statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q4 2025	Q1 2026
Cash & Equivalents	$129.18M	$104.87M	$104.90M	$161.15M
Current Assets	$227.89M	$390.50M	$348.92M	$529.50M
Total Assets	$491.24M	$642.34M	$594.73M	$850.83M
Current Liabilities	$56.45M	$44.39M	$55.01M	$45.06M
Total Debt	$202.46M	$240.73M	$257.32M	$254.83M
Total Liabilities	$1.06B	$1.45B	$1.47B	$300.15M
Retained Earnings	-$604.94M	-$840.85M	-$920.51M	-$1.00B
Shareholders' Equity	-$571.93M	-$804.35M	-$879.03M	$550.67M
Working Capital	$171.44M	$346.10M	$293.91M	$484.44M

EIKN Cash Flow statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$23.74M	-$54.52M	-$41.72M	-$89.80M
Capital Expenditure	-$39.52M	-$22.36M	-$66.00K	-$262.00K
Free Cash Flow	-$63.26M	-$76.88M	-$41.79M	-$90.06M
Depreciation & Amortisation	$6.21M	$6.47M	$5.11M	$5.11M
Stock-Based Compensation	$3.18M	$2.97M	$3.86M	$2.78M
Investing Cash Flow	$8.15M	-$213.85M	$40.71M	-$203.22M
Financing Cash Flow	$95.00K	$350.23M	$1.09M	$349.31M
Net Change in Cash	-$15.49M	$81.86M	$75.00K	$56.29M

Market Snapshot

About

Eikon Therapeutics is a biopharmaceutical company focused on discovering and developing novel treatments for life-threatening diseases. The company utilizes advanced microscopy and computational biology to study protein dynamics in living cells, enabling drug discovery at unprecedented resolution. Eikon's platform technology allows researchers to observe and analyze cellular processes in real-time, identifying potential therapeutic targets. The company is developing a pipeline of small molecule therapeutics aimed at addressing significant unmet medical needs in oncology and other serious conditions.